Revenue from Contracts with Customers |
6 Months Ended |
|---|---|
Jun. 30, 2020 | |
| Revenue from Contract with Customer [Abstract] | |
| Revenue from Contracts with Customers | Revenue from Contracts with Customers
The Company generates substantially all of its revenue from sales of prescription drugs to its customers. Revenue from sales of prescription drugs was $1.3 million and $1.4 million for the three months ended June 30, 2020 and 2019, respectively. Revenue from sales of prescription drugs was $4.1 million and $4.0 million for the six months ended June 30, 2020 and 2019, respectively.
As is typical in the pharmaceutical industry, the Company sells its prescription drugs in the United States primarily through wholesale distributors and a specialty contracted pharmacy. Wholesale distributors account for substantially all of the Company’s net product revenues and trade receivables. In addition, the Company earns revenue from sales of its prescription drugs directly to retail pharmacies. For the three months ended June 30, 2020, the Company’s three largest customers accounted for approximately 50%, 30%, and 18% of the Company's total net product revenues from sale of prescription drugs from continuing operations. For the six months ended June 30, 2020, the Company’s three largest customers accounted for approximately 44%, 29%, and 26% of the Company's total net product revenues from sale of prescription drugs from continuing operations.
|